UroGen Pharma Ltd. (URGN) Monday announced the publication of data from Phase 3b study evaluating the feasibility of at-home instillations of ZUSDURI in patients with recurrent non-muscle invasive bladder cancer (NMIBC) in Reviews in Urology.
In this study, ZUSDURI was administered via urinary catheter. Investigators found no meaningful differences between home and office instillation for most patients. The safety profile was consistent with previous studies, with most adverse events being mild-to-moderate urinary symptoms.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.